Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Melcher

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
Cancer Research|September 10, 2009
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreasTimothy Kottke, Jose Pulido, Jill Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancerLaura Vidal, Hardev S Pandha, Timothy A Yap, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 25, 2014
Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virusElizabeth Ilett, Timothy Kottke, Oliver Donnelly, et al.
Nature Medicine|August 20, 2003
A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccinesVy Phan, Fiona Errington, S Chiat Cheong, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapiesVictoria Roulstone, David Mansfield, Robert J Harris, et al.
Cancer Research|December 20, 2007
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancerTimothy Kottke, Luis Sanchez-Perez, Rosa Maria Diaz, et al.
The Journal of Clinical Investigation|April 6, 2010
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in miceTimothy Kottke, Geoff Hall, Jose Pulido, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 27, 2012
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated miceDiana M Rommelfanger, Marta Compte, Marta C Grau, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 28, 2011
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapyTimothy Kottke, John Chester, Elizabeth Ilett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responsesRichard Harrop, Noel Drury, William Shingler, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
Cancer Research|September 10, 2009
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreasTimothy Kottke, Jose Pulido, Jill Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancerLaura Vidal, Hardev S Pandha, Timothy A Yap, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 25, 2014
Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virusElizabeth Ilett, Timothy Kottke, Oliver Donnelly, et al.
Nature Medicine|August 20, 2003
A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccinesVy Phan, Fiona Errington, S Chiat Cheong, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapiesVictoria Roulstone, David Mansfield, Robert J Harris, et al.
Cancer Research|December 20, 2007
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancerTimothy Kottke, Luis Sanchez-Perez, Rosa Maria Diaz, et al.
The Journal of Clinical Investigation|April 6, 2010
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in miceTimothy Kottke, Geoff Hall, Jose Pulido, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 27, 2012
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated miceDiana M Rommelfanger, Marta Compte, Marta C Grau, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 28, 2011
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapyTimothy Kottke, John Chester, Elizabeth Ilett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responsesRichard Harrop, Noel Drury, William Shingler, et al.
Pageof 14